Trial Profile
Phase III Study to Evaluate Efficacy and Safety of HGP1207 in Patients With Pulmonary Hypertension Associated With Systolic Heart Failure
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sildenafil (Primary)
- Indications Chronic heart failure; Pulmonary arterial hypertension
- Focus Therapeutic Use
- Sponsors Hanmi Pharmaceutical
- 24 Nov 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2018.
- 24 Nov 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2018.
- 14 Mar 2016 Planned End Date changed from 1 Feb 2015 to 1 May 2017, according to ClinicalTrials.gov record.